ANTI-OXIDANT TREATMENT IN AD

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 以安慰剂为对照，评估轻度至中度AD患者服用两种抗氧化剂补充剂方案的安全性和耐受性。活动方案包括维生素E 800 mg+维生素C 200 mg+a-硫辛酸600 mg，每日1次，辅酶Q10800 mg，每日3次。测量抗氧化剂治疗对脑脊液(CSF)氧化损伤生物标志物(即异前列腺素)和神经退行性变(即tau和phosphtau 181)的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To assess the safety and tolerability of two regimens of antioxidant supplements, in comparision to placebo, in participants with mild to moderate AD. The active regimens consist of vitamin E 800 mg + vitamin C 200 mg + a-lipoic acid 600 mg given once per day and coenzyme Q10 800 mg three times a day (TID). To measure the effects of treatment with antioxidants on cerebrospinal fluid (CSF) biomarkers of oxidative damage, namely isoprostanes, and neurodegeneration, namely tau and phosphotau 181.